Bronchitol Gets Final NICE OK, TOBI Podhaler Trumps Colobreathe
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharmaxis’ Bronchitol became the first cystic fibrosis drug to get a NICE final approval, while Novartis’s TOBI Podhaler was selected ahead of Forest Lab’s Colobreathe for bacterial infection.